Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Intec Pharma

- PMLiVE

Novartis turns from social networking to apps for trial recruitment

Launches iPhone and Android cancer trial app in the US

- PMLiVE

Incyte says Jakafi patient developed brain virus

Investigation to determine if myelofibrosis drug is linked to PML

Novartis building

Novartis, ThromboGenics’ eye drug Jetrea gets green light in EU

First drug specifically approved for vitreomacular adhesion

- PMLiVE

Merck & Co’s sugammadex delayed in US

FDA says it needs more time to review application

Novartis building

FDA deems Novartis lung cancer drug a “breakthrough therapy”

LDK378 will have accelerated passage through development

- PMLiVE

Former Amgen R&D head Perlmutter to lead research at Merck & Co

Returns to US pharma firm after more than a decade away

- PMLiVE

Discount convinces NICE to uphold recommendation for Novartis’ Xolair

Asthma drug now also available for children

Novartis building

Novartis’ Ilaris cleared for gouty arthritis in EU

First biologic drug approved for condition in Europe

- PMLiVE

Novartis provides multimedia support to Rare Diseases Day

Collaborates with Eurordis on multimedia education campaign

Novartis to expand SMS for Life approach across Africa

Will broaden reach of mobile-based medicines management programme 

- PMLiVE

Novartis gives Vasella honorary role as payout row continues

Named honorary chairman chairman at Swiss pharma firm after stepping down as chairman

- PMLiVE

Novartis, Roche under scrutiny in Italy on Avastin/Lucentis collusion claims

Antitrust authorities in Italy open investigation into the pharma companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links